Philip Astley-Sparke, Director of enGene Therapeutics ENGN, has filed 0 purchases and 4 sales on the open market. Over the past 12 months that comes to a net sale of $89.7K. The latest trade was on 06/16.

PA

PA

Philip Astley-Sparke

Director

Company

enGene Therapeutics ENGN

First filing

23/04/04

Trades

12 trades

Buys / sales

0 / 4

12-month net buying

−$89.7K

Last trade

06/16

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Replimune GroupREPL	Open-market sale	05/18	05/20	17,657 sh	$5.08	$89,697.56	−1.2%
Replimune GroupREPL	Open-market sale	25/05/20	25/05/22	32,279 sh	$8.06	$260,168.74	−2.2%
Replimune GroupREPL	Open-market sale	24/05/16	24/05/20	37,928 sh	$6.47	$245,394.16	−2.5%
Replimune GroupREPL	Open-market sale	23/05/16	23/05/18	17,902 sh	$18.05	$323,131.1	−1.2%